Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LIPE | Q05469 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20129894 | 0.87 | GAA (0.39) | HSD11B1GAAKCNQ3KCNQ2MAPT | |
| SCHEMBL18177854 | 0.79 | GAA (0.59) | GAAMAPTMEN1KMT2AHTT | |
| SCHEMBL15138249 | 0.79 | MTNR1A (0.40) | GAAMAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL23518502 | 0.78 | HSD11B1 (0.54) | HSD11B1MEN1KMT2AHPGD | |
| SCHEMBL1515374 | 0.78 | HSD11B1 (0.54) | HSD11B1MEN1KMT2AHPGD | |
| SCHEMBL23518575 | 0.78 | HSD11B1 (0.54) | HSD11B1MEN1KMT2AHPGD | |
| SCHEMBL20467895 | 0.77 | GAA (0.44) | HSD11B1GAAKCNQ2MAPTLIPE | |
| SCHEMBL27186331 | 0.77 | GAA (0.35) | GAAMAPTMEN1KMT2AGRIN1 | |
| SCHEMBL29223316 | 0.76 | APLNR (0.34) | GAAKMT2AHPGDGRIN1GRIN2B | |
| SCHEMBL23518503 | 0.76 | GAA (0.39) | HSD11B1GAAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338341-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-11759455-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-09-19 | — | — | US | disclosed |
| US-RE49594-E1 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2023-08-01 | — | — | US | disclosed |
| US-RE49594-E1 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230000833-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-01-05 | — | — | US | disclosed |
| US-11535630-B2 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2022-12-27 | — | — | US | disclosed |
| US-20220162193-A1 | PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS | PELOTON THERAPEUTICS, INC. (US) | 2022-05-26 | — | — | US | disclosed |
| US-11207298-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-28 | — | — | US | disclosed |
| US-20210070767-A1 | APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | RESEARCH TRIANGLE INSTITUTE | 2021-03-11 | — | — | US | disclosed |
| US-20210069155-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-11 | — | — | US | disclosed |
| US-10617676-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-14 | — | — | US | disclosed |
| US-20180125826-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (JP) | 2018-05-10 | — | — | US | disclosed |
| US-20170166577-A1 | APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | RESEARCH TRIANGLE INSTITUTE | 2017-06-15 | — | — | US | disclosed |
| US-20170166577-A1 | APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | RESEARCH TRIANGLE INSTITUTE | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166577-A1 | APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | APLNR, AP1G1, APMAP | HSD11B1 3930/4885GAA 4490/4885KCNQ3 3913/4885 |
| US-11207298-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | HSD11B1 1455/4885GAA 1759/4885KCNQ3 1278/4885 |
| US-11535630-B2 | Apelin receptor (APJ) agonists and uses thereof | APLNR, AP1G1, APMAP | HSD11B1 3930/4885GAA 4490/4885KCNQ3 3913/4885 |
| US-20230000833-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | HSD11B1 1455/4885GAA 1759/4885KCNQ3 1278/4885 |
| US-20210070767-A1 | APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | APLNR, AP1G1, APMAP | HSD11B1 3930/4885GAA 4490/4885KCNQ3 3913/4885 |
| US-20220162193-A1 | PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS | RBM39, RBM3, RBM28 | HSD11B1 3638/4885GAA 3356/4885KCNQ3 4377/4885 |
| US-11759455-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | HSD11B1 1455/4885GAA 1759/4885KCNQ3 1278/4885 |
| US-10617676-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | HSD11B1 1455/4885GAA 1759/4885KCNQ3 1278/4885 |
| US-20210069155-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | HSD11B1 1455/4885GAA 1759/4885KCNQ3 1278/4885 |
| US-20180125826-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | HSD11B1 1455/4885GAA 1759/4885KCNQ3 1278/4885 |
| US-20230338341-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | HSD11B1 1455/4885GAA 1759/4885KCNQ3 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.